Ichikawa T, Kitazaki T, Matsushita Y, Hosono H, Yamada M, Mizuno M, Itoh K
Pharmaceutical Discovery Research Division, Takeda Chemical Indurstries, Ltd, Osaka, Japan.
Chem Pharm Bull (Tokyo). 2000 Dec;48(12):1947-53. doi: 10.1248/cpb.48.1947.
New routes for the synthesis of the optically active antifungal triazoles 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1b) and the 3-14-(1H-1,2,3-triazol-1-yl)phenyl]-2-imidazolidinone analog (1a) that possess an imidazolidine nucleus were established. The key synthetic intermediates, (2R,3R)-3-(2,2-diethoxvethyl)amino-2-(2,4-difluorophenyl)-1-(1H1,2,4-triazol-1-yl)-2-butanol (8) and (2R,3R)-2-(2,4-difiuorophenyl)-3-(2-h ydroxyethyl)amino-1-(1H-1,2,4-triazol-1-yl)-2-butanol (14), were prepared by the ring-opening reaction of the oxirane (2) with the corresponding 2-substituted ethylamines. The acetal (8) was converted to the imidazolidinones (1a, b) by condensation with the carbamates (10a, b) followed by treatment with hydrochloric acid and subsequent catalytic hydrogenation. The candidate selected for the clinical trials, 1b (TAK-456), was alternatively prepared from the hydroxyethylamino intermediate (14) via two reaction steps: condensation with the carbamate (10b) to the urea (15) and subsequent cyclization to the imidazolidinones. This newly developed synthetic route could be applied to a large scale preparation of 1b.
建立了具有咪唑烷核的光学活性抗真菌三唑类化合物1-[(1R,2R)-2-(2,4-二氟苯基)-2-羟基-1-甲基-3-(1H-1,2,4-三唑-1-基)丙基]-3-[4-(1H-1-四唑基)苯基]-2-咪唑烷酮(1b)和3-[4-(1H-1,2,3-三唑-1-基)苯基]-2-咪唑烷酮类似物(1a)的新合成路线。关键合成中间体(2R,3R)-3-(2,2-二乙氧基乙基)氨基-2-(2,4-二氟苯基)-1-(1H-1,2,4-三唑-1-基)-2-丁醇(8)和(2R,3R)-2-(2,4-二氟苯基)-3-(2-羟乙基)氨基-1-(1H-1,2,4-三唑-1-基)-2-丁醇(14)是通过环氧乙烷(2)与相应的2-取代乙胺的开环反应制备的。缩醛(8)通过与氨基甲酸酯(10a,b)缩合,然后用盐酸处理并随后催化氢化,转化为咪唑烷酮(1a,b)。选择用于临床试验的候选物1b(TAK-456)可通过两步反应由羟乙氨基中间体(14)制备:与氨基甲酸酯(10b)缩合生成脲(15),随后环化生成咪唑烷酮。这种新开发的合成路线可应用于1b的大规模制备。